GlassScriptPhysician profile
Melodye Campbell
NPI 1780054452
$4,170.29
in general payments reported to CMS, 2019-2025
31 companies · $1,263 in 2025
The $1,263 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $186 · 2022: $762 · 2023: $920 · 2024: $1,039 · 2025: $1,263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,221.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $678.67 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $615.70 | 2022-2025 | |
| Lilly USA, LLC | $356.74 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $303.91 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $263.94 | 2022-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.39 | 2022-2025 | Jardiance |
| Exact Sciences Corporation | $203.92 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $192.63 | 2022 | |
| Glaxosmithkline, LLC. | $184.17 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $164.50 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $151.14 | 2022-2025 | |
| Astellas Pharma US INC | $106.14 | 2021-2025 | Veozah, Myrbetriq |
| Axsome Therapeutics, INC. | $100.70 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $76.79 | 2022-2024 | Trintellix |
| Amgen INC. | $72.81 | 2021-2025 | Repatha, Otezla, Repatha |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $64.89 | 2024 | Flucelvax, Fluad |
| Daiichi Sankyo INC. | $60.34 | 2021-2022 | |
| Esperion Therapeutics, INC. | $47.81 | 2021-2025 | Nexletol |
| Dynavax Technologies Corporation | $43.80 | 2023-2025 | Heplisav-B |
| Astrazeneca Pharmaceuticals LP | $37.75 | 2023-2024 | Farxiga |
| Abbott Laboratories | $36.56 | 2023-2024 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $30.87 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $29.15 | 2021 | |
| Stryker Corporation | $28.24 | 2025 | Clottriever Bold Catheter |
| Janssen Pharmaceuticals, INC | $17.57 | 2022 | |
| Phathom Pharmaceuticals, INC. | $17.31 | 2024 | Voquezna |
| Insulet Corporation | $17.25 | 2024 | Omnipod |
| Ultragenyx Pharmaceutical INC. | $15.17 | 2022 | |
| Ironwood Pharmaceuticals, INC | $14.77 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $14.36 | 2025 | Rexulti |
| Dexcom, INC. | $11.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melodye Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.